{"entity":{"id":"idea-fund-proton-coverage-with-evidence","kind":"idea","name":"Pooled coverage-with-evidence for proton therapy across all centres","aka":[],"tldr":"Proton therapy costs far more than standard radiotherapy and, for most adult cancers, nobody knows whether it is better. Payers would cover it only inside trials or registries that answer that question, across every centre at once.","summary":"National payers and proton centres agree that reimbursement for adult indications without established benefit is conditional on enrolment in pragmatic randomised trials (proton versus photon) or, where randomisation is unacceptable, in a common prospective registry with matched photon comparators, pooled internationally. Existing trials (PARTIQoL in prostate, RADCOMP in breast, NRG lung and oesophageal trials) have struggled with accrual partly because patients can obtain protons outside trials. Pooling and conditioning payment fixes accrual and produces evidence proportionate to the investment already made in dozens of centres.","asOf":"2026-09-08","links":[{"label":"PARTIQoL (NCT01617161)","url":"https://clinicaltrials.gov/study/NCT01617161"},{"label":"RADCOMP (NCT02603341)","url":"https://clinicaltrials.gov/study/NCT02603341"}],"tags":[],"related":["idea-fund-flash-evidence-programme","idea-fund-adaptive-radiotherapy-evidence","idea-bio2-let-rbe-ab-selects-protons","proton-vs-imrt"],"cancers":["prostate","breast-hr-positive","esophageal"],"sections":[],"technologies":["proton-therapy","carbon-ion","imrt-igrt"],"targets":[],"drugs":[],"companies":["iba","mevion"],"institutions":[],"pathways":[],"terms":["relative-biological-effectiveness","linear-energy-transfer","alpha-beta-ratio"],"trials":["partiqol","radcomp"],"people":["juergen-debus"],"bottlenecks":["b-surgery-radiation-innovation","b-drug-pricing"],"keyPapers":["paper-partiqol-astro-2024"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Coverage-with-evidence conditions triple accrual to randomised proton versus photon trials within three years and produce definitive comparative results in at least three common adult indications within six.","rationale":"The Netherlands' model-based indication protocol and coverage-with-evidence in several US insurers show payers can condition access; the proton field itself has called for randomised evidence for two decades and has produced little because the incentives run the other way.","test":"Implement the condition across a payer coalition for two adult indications and compare trial accrual rates and time to completion with the period before.","maturity":"being-tested-at-scale","actor":"payer","cost":"large","horizonYears":5},"route":"/ideas/idea-fund-proton-coverage-with-evidence/","neighbours":{"idea":[{"id":"idea-fund-flash-evidence-programme","kind":"idea","name":"A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards","route":"/ideas/idea-fund-flash-evidence-programme/"},{"id":"idea-fund-adaptive-radiotherapy-evidence","kind":"idea","name":"Coverage-with-evidence registries for MR-guided and adaptive radiotherapy","route":"/ideas/idea-fund-adaptive-radiotherapy-evidence/"},{"id":"idea-bio2-let-rbe-ab-selects-protons","kind":"idea","name":"Use LET, RBE and alpha/beta to decide when protons beat IMRT","route":"/ideas/idea-bio2-let-rbe-ab-selects-protons/"}],"pairing":[{"id":"proton-vs-imrt","kind":"pairing","name":"Caution: proton therapy vs IMRT","route":"/pairings/proton-vs-imrt/"}],"cancer":[{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"carbon-ion","kind":"technology","name":"Carbon-ion therapy","route":"/technologies/carbon-ion/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"}],"company":[{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/"},{"id":"mevion","kind":"company","name":"Mevion Medical Systems","route":"/companies/mevion/"}],"term":[{"id":"alpha-beta-ratio","kind":"term","name":"Alpha/beta ratio","route":"/terms/alpha-beta-ratio/"},{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/"},{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/"}],"trial":[{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/"},{"id":"radcomp","kind":"trial","name":"RADCOMP","route":"/trials/radcomp/"}],"person":[{"id":"juergen-debus","kind":"person","name":"Jürgen Debus","route":"/people/juergen-debus/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/"}],"paper":[{"id":"paper-partiqol-astro-2024","kind":"paper","name":"PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)","route":"/key-papers/paper-partiqol-astro-2024/"}]}}